AMERICAN HOME PRODUCTS CORP
SC 13D/A, EX-9, 2000-06-26
PHARMACEUTICAL PREPARATIONS
Previous: AMERICAN HOME PRODUCTS CORP, SC 13D/A, 2000-06-26
Next: FEDERATED AMERICAN LEADERS FUND INC, 425, 2000-06-26



                                                               EXHIBIT IX

                     MDP ASSIGNMENT AND ACCEPTANCE AGREEMENT

     THIS  AGREEMENT,  dated  June 26,  2000  (this  "Agreement"),  by and among
Immunex  Corporation,  a  Washington  corporation  ("Immunex"),   American  Home
Products Corporation, a Delaware corporation ("AHP"), American Cyanamid Company,
a Maine corporation ("Cyanamid"),  and MDP Holdings, Inc, a Delaware corporation
("MDP").

     WHEREAS,  Immunex entered into the Amended and Restated  Agreement and Plan
of Merger, dated as of December 15, 1992 (the "Immunex Merger Agreement"),  with
Cyanamid,  Lederle  Parenterals,  Inc. ("LPI") and Lederle Oncology  Corporation
("LOC") and an Amended and Restated Governance  Agreement,  dated as of December
15, 1992 (the "Governance Agreement"), with Cyanamid and LOC;

     WHEREAS, upon consummation of the merger contemplated by the Immunex Merger
Agreement  (the  "Immunex  Merger"),  Cyanamid  and LPI  became  the  owners  of
approximately  53.5% of the issued and outstanding  common stock of Immunex (the
"Immunex Common Stock");

     WHEREAS,  the  Governance  Agreement  was  entered  into by the  parties in
connection with the Immunex Merger Agreement in order to establish certain terms
and  conditions  concerning  (a) the  corporate  governance of Immunex after the
Immunex Merger and (b) the  acquisition and disposition of securities of Immunex
by Cyanamid;

     WHEREAS, AHP entered into an Agreement and Plan of Merger, dated August 17,
1994 (the "AHP Merger  Agreement"),  with AC  Acquisition  Corp.  and  Cyanamid,
pursuant to which AHP acquired all of the issued and  outstanding  capital stock
of Cyanamid;

     WHEREAS, following the consummation of the tender offer required by the AHP
Merger  Agreement,  AHP  became  the  beneficial  owner of the shares of Immunex
Common Stock owned by Cyanamid;

     WHEREAS,  AHP and Immunex  entered into an Agreement,  dated  September 23,
1994, pursuant to which (a) Immunex made certain  representations  regarding its
Board of Directors'  approval of the beneficial  ownership by AHP of the Immunex
Common Stock and (b) AHP agreed to take certain actions to assure Cyanamid's and
its subsidiary's compliance with the Governance Agreement;

     WHEREAS,  AHP and Cyanamid each has requested that Immunex cooperate in the
transfer of all of the Immunex  common  stock  currently  held by Cyanamid  (the
"Cyanamid Holdings") to MDP, a wholly-owned  subsidiary of Cyanamid, and Immunex
has, on the terms set forth  below,  agreed to take such  actions  necessary  to
facilitate such transfer;

     WHEREAS,  in  connection  with  such  transfer  of the  Cyanamid  Holdings,
Cyanamid desires to assign certain of its rights under the Governance Agreement,
including its registration rights with regard to the Cyanamid Holdings, to MDP;

     WHEREAS,  Section 9.04 of the Governance  Agreement  provides that Cyanamid
may assign all or any of its rights  and  obligations  thereunder  to any of its
wholly-owned  subsidiaries;  provided that (a) no such  assignment  will relieve
Cyanamid of its obligations under the Governance  Agreement and (b) Cyanamid may
assign its rights as provided in Section 6.13 thereunder.

     WHEREAS,  Section 6.13 of the Governance  Agreement  provides that Cyanamid
may  transfer  its  registration  rights  under the  Governance  Agreement  to a
wholly-owned  subsidiary of Cyanamid;  provided that (a) Cyanamid  complies with
certain notice  requirements,  (b) such transferee agrees in writing,  in a form
reasonably  satisfactory  to  Immunex,  to be bound as a Holder  (defined in the
Governance  Agreement) by the registration  rights  provisions of the Governance
Agreement,  and (c) immediately following such transfer Holder acknowledges that
the future  disposition  of the  transferred  securities  by the  transferee  is
restricted  under the  Securities  Act of 1933,  and the  rules and  regulations
promulgated thereunder, as amended.

     NOW, THEREFORE, in consideration of the foregoing and other mutual promises
and agreements contained herein,  Immunex, AHP, Cyanamid and MDP hereby agree as
follows:

     1. Defined  Terms.  Capitalized  terms used herein and not defined have the
meanings given to such terms in the Governance Agreement.

     2. Status of MDP. AHP,  Cyanamid and MDP each  represents and warrants that
(a)  MDP is a  wholly-owned  subsidiary  of  Cyanamid  duly  organized,  validly
existing  and in good  standing  under the laws of Delaware  and (b) MDP has the
corporate power and authority and legal right to enter into this Agreement.

     3.  Assignment  of  Subscription  Rights.  Pursuant to Section  9.04 of the
Governance  Agreement,  Cyanamid hereby assigns to MDP all of Cyanamid's  rights
and  obligations  under Article II of the Governance  Agreement.  Immunex hereby
acknowledges  such  assignment.  Cyanamid,  Immunex and MDP each agree that such
assignment  shall be revocable by Cyanamid  upon  delivery of written  notice to
Immunex.

     4. Acceptance of Subscription Rights and Transfer Restrictions.  MDP hereby
accepts the rights and obligations under Article II of the Governance  Agreement
assigned to it by Cyanamid.  In addition,  in  connection  with its ownership of
securities  of  Immunex,  MDP  agrees  that,  to the  extent  that the  transfer
restrictions  within  Article  V of the  Governance  Agreement  would  apply  to
securities  of  Immunex  held by  Cyanamid,  MDP  shall  be  bound  by all  such
restrictions.

     5.  Assignment  of  Registration  Rights.  Pursuant to Section  6.13 of the
Governance  Agreement,   Cyanamid  hereby  assigns  to  MDP  all  of  Cyanamid's
registration  rights as a Holder of the Cyanamid  Holdings.  In accordance  with
Section 6.13 of the Governance  Agreement,  Cyanamid hereby notifies  Immunex of
the transfer of the Cyanamid  Holdings to MDP, which has its principal  place of
business at 1403 Foulk Road, Suite 102, Wilmington, Delaware 19803.

     6. Acceptance of Registration  Rights and  Obligations.  MDP hereby accepts
the rights and obligations under Article VI of the Governance Agreement assigned
to it by  Cyanamid.  In  addition,  in  accordance  with  Section  6.13  of  the
Governance  Agreement,  MDP  hereby  agrees  to be  bound  as a  Holder  by  the
provisions  of  Article  VI  of  the   Governance   Agreement.   Immunex  hereby
acknowledges  the assignment of registration  rights to MDP and its satisfaction
with  MDP's  assumption  of the  obligations  of  Article  VI of the  Governance
Agreement.

     7.  Protection of Governance  Agreement.  During the term of the Governance
Agreement:

     7.1 AHP and Cyanamid  each agrees that (a) it will not take action to cause
MDP to violate its obligations  hereunder or under the Governance  Agreement and
(b) it will not fail to permit MDP to take any action as may be  required  to be
taken by MDP to perform such obligations.

     7.2 If either AHP or Cyanamid  directly or  indirectly  causes the separate
existence of MDP to cease  (whether by merger,  consolidation  or other  similar
business   combination   transaction),   or  causes  MDP  to  transfer   all  or
substantially  all of its  assets in one  transaction  or in a series of related
transaction,   AHP  and  Cyanamid  will  each,  in  connection  therewith,  make
appropriate  provision  so  that  any  successor  to,  or  transferee  of all or
substantially  all of the  assets of,  MDP that is an  affiliate  of AHP will be
bound by and required to perform the obligations of MDP under this Agreement and
the Governance Agreement.

     8. Amendments,  Waivers.  Any provision of this Agreement may be amended or
waived if,  and only if,  such  amendment  or  waiver is in writing and signed,
in the case of an amendment,  by Immunex,  AHP, Cyanamid and MDP, or in the case
 of a waiver,  by the party  against whom the waiver is to be effective.

     9. Counterparts. This Agreement may be executed and delivered (including by
way of facsimile transmission) in counterparts, each of which, when executed
and  delivered,  shall be deemed to be an  original  and all of which, taken
together, shall constitute one and the same instrument.


<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed by their representative authorized officer as of the day and year
first above written.


                                      IMMUNEX CORPORATION


                                      By:_________________________________
                                      Name:
                                      Title:

                                      AMERICAN HOME PRODUCTS CORPORATION


                                      By:_________________________________
                                      Name:
                                      Title:

                                      AMERICAN CYANAMID COMPANY


                                      By:_________________________________
                                      Name:
                                      Title:

                                      MDP HOLDINGS, INC.


                                      By:_________________________________
                                      Name:
                                      Title:



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission